Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS-LUNG umbrella study in metastatic non-small cell lung cancer
MOH_2019-08-25_007278Phase 2Recruiting
- Sponsor
- Roche
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) and bronchial carcinoma (8 arms), sponsored by Roche. Primary endpoint: Efficacy and safety. Started Aug 2019; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on MOH_2019-08-25_007278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-25_007278.